Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$15.00 +4.7%	$14.30	$10.57 ▼ $33.33	$2.08B	1.33	1.14 million shs	2.02 million shs
INDV Indivior	$15.14 -0.2%	$12.94	$7.33 ▼ $15.88	N/A	0.65	1.24 million shs	1.17 million shs
ORGO Organogenesis	$4.46 -3.7%	$3.55	$2.28 ▼ $6.71	$587.33M	1.7	1.15 million shs	743,390 shs
RXRX Recursion Pharmaceuticals	$5.59 +4.3%	$4.82	$3.79 ▼ $12.36	$2.18B	0.91	16.40 million shs	34.34 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	+0.56%	+2.72%	-2.52%	+11.43%	-32.37%
INDV Indivior	-2.44%	+3.48%	+7.82%	+56.55%	-1.11%
ORGO Organogenesis	+8.94%	+22.49%	+52.81%	+13.48%	+64.77%
RXRX Recursion Pharmaceuticals	+8.72%	+4.48%	-2.37%	+15.27%	-27.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNLI Denali Therapeutics	4.5778 of 5 stars	4.5	2.0	4.7	2.6	2.5	0.0
INDV Indivior	2.6274 of 5 stars	2.6	3.0	0.0	1.9	1.7	1.9
ORGO Organogenesis	4.3359 of 5 stars	3.0	3.0	4.3	1.9	4.2	0.6
RXRX Recursion Pharmaceuticals	1.9534 of 5 stars	3.2	1.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	3.06	Buy	$33.71	124.76% Upside
INDV Indivior	3.25	Buy	$17.00	12.29% Upside
ORGO Organogenesis	2.00	Hold	$6.00	34.53% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	25.22% Upside

Current Analyst Ratings Breakdown

Latest ORGO, RXRX, DNLI, and INDV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/30/2025	INDV Indivior	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $22.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
5/6/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
4/24/2025	DNLI Denali Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/10/2025	DNLI Denali Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	6.59	N/A	N/A	$8.53 per share	1.76
INDV Indivior	$1.19B	N/A	$1.82 per share	8.33	($2.52) per share	N/A
ORGO Organogenesis	$482.04M	1.17	$0.20 per share	22.19	$2.09 per share	2.13
RXRX Recursion Pharmaceuticals	$58.84M	38.62	N/A	N/A	$2.61 per share	2.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$422.77M	-$2.67	0.00	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
INDV Indivior	$2M	-$0.31	8.87	8.85	N/A	-4.02%	-97.29%	15.74%	7/24/2025 (Estimated)
ORGO Organogenesis	$860K	-$0.17	0.00	N/A	N/A	-3.46%	-4.00%	-2.26%	8/6/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.77	0.00	N/A	N/A	-961.32%	-74.70%	-54.02%	8/6/2025 (Estimated)

Latest ORGO, RXRX, DNLI, and INDV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	INDV Indivior	$0.25	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	ORGO Organogenesis	$0.04	-$0.13	-$0.17	-$0.17	$90.77 million	$86.69 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	N/A	9.56	9.56
INDV Indivior	N/A	0.88	0.72
ORGO Organogenesis	N/A	4.12	3.67
RXRX Recursion Pharmaceuticals	0.02	4.11	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
INDV Indivior	60.33%
ORGO Organogenesis	49.57%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	12.50%
INDV Indivior	N/A
ORGO Organogenesis	33.00%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
INDV Indivior	1,051	N/A	N/A	Not Optionable
ORGO Organogenesis	950	126.85 million	84.99 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.49 million	372.23 million	Optionable

ORGO, RXRX, DNLI, and INDV Headlines

Recent News About These Companies

Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia

5 hours ago | insidermonkey.com

Recursion Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RXRX)

July 9 at 2:11 PM | marketbeat.com

RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program

July 9 at 1:01 PM | zacks.com

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M

July 9 at 11:55 AM | finance.yahoo.com

10 Under-the-Radar Tech Stocks With Incredible Growth Potential

July 9 at 4:23 AM | fool.com

Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking

July 8 at 3:08 PM | insidermonkey.com

Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

July 8 at 1:30 PM | finanznachrichten.de

Recursion Pharmaceuticals Stock Gains on Plans to Buy Drug-Development Interest from Rallybio

July 8 at 1:30 PM | marketwatch.com

Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio

July 8 at 1:30 PM | in.investing.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.7% Higher - Should You Buy?

July 8 at 12:39 PM | marketbeat.com

Recursion Pharmaceuticals' (RXRX) Buy Rating Reaffirmed at Needham & Company LLC

July 8 at 11:21 AM | marketbeat.com

10 Stocks Crash Hard Alongside Wall Street

July 8 at 8:30 AM | insidermonkey.com

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

July 8 at 8:30 AM | finance.yahoo.com

What's Happening With RXRX Stock?

July 8 at 8:05 AM | forbes.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 6.2% - Here's Why

July 7 at 11:55 AM | marketbeat.com

Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?

July 7 at 11:26 AM | zacks.com

Morgan Stanley Initiates Coverage on Recursion Pharmaceuticals (NASDAQ:RXRX)

July 5, 2025 | americanbankingnews.com

Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today

July 3, 2025 | zacks.com

What Analysts Are Saying About Recursion Pharmaceuticals Stock

July 3, 2025 | benzinga.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Earns Equal Weight Rating from Analysts at Morgan Stanley

July 3, 2025 | marketbeat.com

Kinnevik AB publ Has $71.07 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

July 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, RXRX, DNLI, and INDV Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$15.00 +0.67 (+4.68%)

Closing price 04:00 PM Eastern

Extended Trading

$15.22 +0.22 (+1.43%)

As of 06:16 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Indivior NASDAQ:INDV

$15.14 -0.03 (-0.20%)

Closing price 04:00 PM Eastern

Extended Trading

$15.14 +0.00 (+0.03%)

As of 04:31 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Organogenesis NASDAQ:ORGO

$4.46 -0.17 (-3.67%)

Closing price 04:00 PM Eastern

Extended Trading

$4.70 +0.24 (+5.47%)

As of 07:21 PM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.59 +0.23 (+4.29%)

Closing price 04:00 PM Eastern

Extended Trading

$5.70 +0.12 (+2.06%)

As of 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time